The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.
about
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria SyndromeProgeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxideSeeking a Cure for One of the Rarest Diseases: Progeria.Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome.
P2860
The decision-making process and criteria in selecting candidate drugs for progeria clinical trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The decision-making process an ...... for progeria clinical trials.
@en
The decision-making process an ...... for progeria clinical trials.
@nl
type
label
The decision-making process an ...... for progeria clinical trials.
@en
The decision-making process an ...... for progeria clinical trials.
@nl
prefLabel
The decision-making process an ...... for progeria clinical trials.
@en
The decision-making process an ...... for progeria clinical trials.
@nl
P2093
P2860
P356
P1476
The decision-making process an ...... for progeria clinical trials.
@en
P2093
Mark W Kieran
Monica E Kleinman
Tom Misteli
P2860
P304
P356
10.15252/EMMM.201606280
P577
2016-05-26T00:00:00Z